Literature DB >> 19393294

The genetics of schizophrenia.

A Bertolino1, G Blasi.   

Abstract

Research on the genetic factors conferring risk for schizophrenia has not provided definitive answers. In the present review, we will discuss potential clinical and genetic limitations intrinsic to the strategies using a diagnostic phenotype. Among clinical factors, uncertainty of the phenotype is certainly a major limitation. Genetic problems include locus heterogeneity and the complex genetic architecture of the phenotype. Given these limiting factors, we will also discuss another hypothesis-driven strategy to uncover genetic risk: the use of quantitative measures (intermediate phenotypes) within more specific neurobiological mechanisms. As a clear example of all these issues and because of the longstanding involvement in the pathophysiology of this disorder, we will review the association of the gene for dopamine D2 receptors (DRD2) with diagnosis of schizophrenia and with specific working memory behavioral and brain activity phenotypes. We conclude by suggesting that hypothesis-free and hypothesis-driven are not mutually exclusive strategies and may provide information at different levels that are both useful and equally valid about genetic risk for a complex diagnostic entity like schizophrenia and for a complex phenotype like psychosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19393294     DOI: 10.1016/j.neuroscience.2009.04.038

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  20 in total

1.  BDNF rs6265 methylation and genotype interact on risk for schizophrenia.

Authors:  Gianluca Ursini; Tommaso Cavalleri; Leonardo Fazio; Tiziana Angrisano; Luisa Iacovelli; Annamaria Porcelli; Giancarlo Maddalena; Giovanna Punzi; Marina Mancini; Barbara Gelao; Raffaella Romano; Rita Masellis; Francesca Calabrese; Antonio Rampino; Paolo Taurisano; Annabella Di Giorgio; Simona Keller; Letizia Tarantini; Lorenzo Sinibaldi; Tiziana Quarto; Teresa Popolizio; Grazia Caforio; Giuseppe Blasi; Marco A Riva; Antonio De Blasi; Lorenzo Chiariotti; Valentina Bollati; Alessandro Bertolino
Journal:  Epigenetics       Date:  2016-02-18       Impact factor: 4.528

2.  DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.

Authors:  Giuseppe Blasi; Francesco Napolitano; Gianluca Ursini; Paolo Taurisano; Raffaella Romano; Grazia Caforio; Leonardo Fazio; Barbara Gelao; Annabella Di Giorgio; Luisa Iacovelli; Lorenzo Sinibaldi; Teresa Popolizio; Alessandro Usiello; Alessandro Bertolino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

3.  New findings in the genetics of schizophrenia.

Authors:  Ladislav Hosak
Journal:  World J Psychiatry       Date:  2013-09-22

4.  From the genome to the phenome and back: linking genes with human brain function and structure using genetically informed neuroimaging.

Authors:  H R Siebner; J H Callicott; T Sommer; V S Mattay
Journal:  Neuroscience       Date:  2009-09-12       Impact factor: 3.590

5.  Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics.

Authors:  Giuseppe Blasi; Pierluigi Selvaggi; Leonardo Fazio; Linda Antonella Antonucci; Paolo Taurisano; Rita Masellis; Raffaella Romano; Marina Mancini; Fengyu Zhang; Grazia Caforio; Teresa Popolizio; Jose Apud; Daniel R Weinberger; Alessandro Bertolino
Journal:  Neuropsychopharmacology       Date:  2015-01-07       Impact factor: 7.853

6.  Multivariate classification of schizophrenia and its familial risk based on load-dependent attentional control brain functional connectivity.

Authors:  Linda A Antonucci; Nora Penzel; Giulio Pergola; Lana Kambeitz-Ilankovic; Dominic Dwyer; Joseph Kambeitz; Shalaila Siobhan Haas; Roberta Passiatore; Leonardo Fazio; Grazia Caforio; Peter Falkai; Giuseppe Blasi; Alessandro Bertolino; Nikolaos Koutsouleris
Journal:  Neuropsychopharmacology       Date:  2019-10-03       Impact factor: 7.853

7.  A splicing-regulatory polymorphism in DRD2 disrupts ZRANB2 binding, impairs cognitive functioning and increases risk for schizophrenia in six Han Chinese samples.

Authors:  O S Cohen; T W Weickert; J L Hess; L M Paish; S Y McCoy; D A Rothmond; C Galletly; D Liu; D D Weinberg; X-F Huang; Q Xu; Y Shen; D Zhang; W Yue; J Yan; L Wang; T Lu; L He; Y Shi; M Xu; R Che; W Tang; C-H Chen; W-H Chang; H-G Hwu; C-M Liu; Y-L Liu; C-C Wen; C S-J Fann; C-C Chang; T Kanazawa; F A Middleton; T M Duncan; S V Faraone; C S Weickert; M T Tsuang; S J Glatt
Journal:  Mol Psychiatry       Date:  2015-09-08       Impact factor: 15.992

Review 8.  The molecular pathology of schizophrenia--focus on histone and DNA modifications.

Authors:  Schahram Akbarian
Journal:  Brain Res Bull       Date:  2009-09-01       Impact factor: 4.077

9.  Associations of prenatal nicotine exposure and the dopamine related genes ANKK1 and DRD2 to verbal language.

Authors:  John D Eicher; Natalie R Powers; Kelly Cho; Laura L Miller; Kathryn L Mueller; Susan M Ring; J Bruce Tomblin; Jeffrey R Gruen
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

10.  Strategies for Psychiatric Rehabilitation and their Cognitive Outcomes in Schizophrenia: Review of Last Five-year Studies.

Authors:  Antonio Rampino; Rosa M Falcone; Arianna Giannuzzi; Rita Masellis; Linda A Antonucci; Silvia Torretta
Journal:  Clin Pract Epidemiol Ment Health       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.